Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
June 3, 2024 4:03 PM EDTCiti analyst David Lebowitz reiterated a Neutral rating and $29.00 price target on Arrowhead Pharma (NASDAQ: ARWR)
The analyst comments "Plozasiran succeeded in Ph3 PALISADE trial in familial chylomicronemia syndrome (FCS), showing up to 80% triglyceride (TG) lowering at Month-10 at 25 and 50mg quarterly doses,... More
